BCYC240816C20000
- 0.00
- 0.000.00%
Bicycle Therapeutics Newsroom
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
European Equities Traded in the US as American Depositary Receipts Open Week Strong Monday Trading
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Bicycle Therapeutics: Buy Rating Affirmed on Strong Q2 Financials and Promising Pipeline Developments
The Latest Analyst Ratings For Bicycle Therapeutics
Bicycle Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Bicycle Therapeutics Cut at B. Riley Ahead of Data Readouts
Express News | Bicycle Therapeutics Shares Are Trading Lower After B. Riley Securities Downgraded the Stock From Buy to Neutral and Lowered Its Price Target From $33 to $28
Express News | Oppenheimer Maintains Outperform on Bicycle Therapeutics, Maintains $48 Price Target
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
Positive Clinical Prospects for Bicycle Therapeutics' Drug Candidates at ESMO Congress May Strengthen Market Position
5Needham Reiterates Buy on Bicycle Therapeutics, Maintains $38 Price Target
Express News | B. Riley Securities Downgrades Bicycle Therapeutics to Neutral, Lowers Price Target to $28
Bicycle Therapeutics: Hold Rating Amid Clinical and Competitive Challenges
Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (INSP), Definitive Healthcare Corp (DH) and Bicycle Therapeutics (BCYC)
Buy Rating Affirmed for Bicycle Therapeutics Amidst Strategic Growth and Strong Financial Position
Express News | Bicycle Therapeutics PLC : B. Riley Cuts Target Price to $28 From $33
Express News | Bicycle Therapeutics PLC : B. Riley Cuts to Neutral From Buy